March 2022 COVID-19 Updates
Background:
Two manufacturers of Covid-19 vaccines have submitted additional requests for Emergency Use Authorization (EUA) for children ages 6 months to 4 years and boosters for those fully vaccinated adults. There is a new Covid-19 test to identify mutations as well. We feel it is important to keep you abreast of the latest Covid-19 news in this ever-changing environment. This release highlights the new codes released by the American Medical Association (AMA) and provides details of the new diagnosis codes for Covid-19 vaccine status, taking effect on April 1, 2022.
Please note the following:
-
- The Food and Drug Administration (FDA) has postponed the review of the Pfizer Vaccination for children ages 6 months to 4 years until all the clinical trial data is available for review.
- Pfizer summited a request for EUA for a booster for adults 65 or older who are at risk of severe illness from Covid-19, the FDA is currently reviewing the request.
- The FDA authorized shortening of the time period for Pfizer boosters to five months.
- Moderna received approval from the FDA to market its Covid-19 vaccine under the trade name of Spikevax in January of 2022.
- Moderna also submitted a EUA request for a second booster for those over the age of 18 which the FDA is currently reviewing.
- The AMA has published additional vaccine and administration codes pending the EUA for the boosters and new vaccines.
- The AMA released a new CPT code (87913) to test for mutations of Covid-19 on 2-21-2022.
- The Center for Disease Control (CDC) has released new diagnosis codes to reflect Covid-19 vaccination status.
- Breaking news: Moderna will be submitting a request for EUA for vaccination for children ages 6 months to 6 years of age next week based on the results of their clinical trial per media reports.
Below are the Vaccination Status Diagnosis Codes Released by the CDC
| Diagnosis Code | Description | Effective Date |
| Z28.311 | Partial Vaccination for Covid-19 | 4/1/22 |
| Z28.310 | Unvaccinated for Covid-19 | 4/1/22 |
| Z28.39 | Other Under Immunization Status | 4/1/22 |
New Test for Covid-19 Mutations
| CPT Code | Description | Effective Date |
| 87913 | NFCT AGENT GENOTYPE ALYS NUCLEIC ACID SARSCOV2 | 2/21/22 |
New Vaccine and Administration Codes
| Code | Description | EUA Date | Manufacturer | Age Group | Dosage |
| 91307 | Vaccine-reconstituted | 10/29/21 | Pfizer | 5-11 Years | 10 mcg/0.2 ml |
| 0071A | Admin 1st Dose | 10/29/21 | Pfizer | 5-11 Years | 10 mcg/0.2 ml |
| 0072A | Admin 2nd Dose | 10/29/21 | Pfizer | 5-11 Years | 10 mcg/0.2 ml |
| 0073A | Admin 3rd Dose | 1/3/22 | Pfizer | 5-11 Years | 10 mcg/0.2 ml |
| Code | Description | EUA Date | Manufacturer | Age Group | Dosage |
| 91308 | Vaccine-reconstituted | Pending | Pfizer | 6 Mo – 4 Years | 3 mcg/0.2 mL |
| 0081A | Admin 1st Dose | Pending | Pfizer | 6 Mo – 4 Years | 3 mcg/0.2 mL |
| 0082A | Admin 2nd Dose | Pending | Pfizer | 6 Mo – 4 Years | 3 mcg/0.2 mL |
| Code | Description | EUA Date | Manufacturer | Age Group | Dosage |
| 91309 | Vaccine | Pending | Moderna | Over 18 | 50 mcg/0.5 mL |
| 0094A | Admin booster | Pending | Moderna | Over 18 | 50 mcg/0.5 mL |
Reference Materials:
- MLN Link MM12578. January 14, 2022
https://www.cms.gov/files/document/mm12578-april-2022-update-medicare-severity-diagnosis-related-group-ms-drg-grouper-and-medicare-code.pdf
- AMA Discussion on Vaccine Status for Kids
https://www.ama-assn.org/delivering-care/public-health/tsa-mask-mandate-updates-covid-vaccines-kids-andrea-garcia-jd-mph
- FDA Press Release January 3, 2022
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-multiple-actions-expand-use-pfizer-biontech-covid-19-vaccine
- HealthLeaders Media Article on Moderna Seeking EUA
https://www.npr.org/2022/03/23/1088167753/moderna-covid-19-vaccine-children-fda
If you are interested in learning more about Codoxo’s forensic AI platform or would like to speak to Codoxo team member, contact us via info@codoxo.com.
